Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CM326
- Development stage
- Phase 3
- Lead developer
- Keymed Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
CM326 is a humanized monoclonal antibody that targets thymic stromal lymphopoietin (TSLP), acting as a TSLP inhibitor. It is designed to block TSLP-mediated Th2-driven inflammation, which plays a pivotal role in various allergic and inflammatory diseases. Preclinical studies demonstrated that CM326 has higher potency than tezepelumab in inhibiting Th2 inflammation and improving lung function. Clinical trials have evaluated its safety, tolerability, pharmacokinetics, and immunogenicity in healthy adults and patients with conditions such as asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. The drug is administered subcutaneously. It is currently under development primarily for moderate-to-severe asthma and atopic dermatitis among other respiratory inflammatory diseases.
- Other names
- CM-326CM326CM 326
02
Targets
TSLP (Thymic stromal lymphopoietin)
Beyond the preview
Go deeper on CM326.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CM326.